Solara Active Pharma Sciences Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Solara Active Pharma Sciences reported its highest revenue, gross margins, and EBITDA in 8 quarters for Q4 FY26. Revenue grew 12% QoQ to INR 392 Cr, with EBITDA up 65% to INR 61 Cr (16% margin). The profitable base business, with 26% EBITDA and 54% gross margins, was the primary driver. Solara aims to be debt-free by FY29, having reduced debt by INR 158 Cr in FY26. Management is evaluating strategic options for the loss-making ibuprofen business, expecting a decision by H1 FY27. They plan 4-5 annual DMF filings to drive future growth from FY29-31, focusing on existing capacity utilization and operational efficiency. Sentiment: Confident in sustained profitable growth.